Free Newsletter
Device beats drugs for atrial fib
A Johnson & Johnson unit released study data yesterday showing that its catheter-based system might be more effective than drugs are at resolving heart arrhythmias. The company's Biosense Webster unit is hoping to gain FDA approval to market the device for the treatment of atrial fibrillation, making it the first approved device to treat the condition. AtriCure , Boston Scientific, Medtronic and St. Jude Medical all have competing devices, but none have received FDA approval for the condition to date. Report
Be the first to comment
More stories about Johnson & Johnson
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


